Xspray-logo-white
  • Home
  • About us
    • Business model
    • Our history – a timeline
    • Board of Directors & Board committees
    • Management
  • Technology
  • Pipeline
  • Media
  • Contact
  • Investors
  • en en
    • sv sv
  • Investors
    • Share information
      • Ownership structure
    • Financial calendar
    • Financial reports
      • ESEF report
    • Prospectus
    • Press releases
    • Corporate governance
      • Corporate Structure
      • General meetings
      • Corporate Governance Reports
      • Nomination committee
      • Board of Directors & Board committees
      • Management
      • Accounting principles
      • Internal control & Risk management
      • Auditor
      • Articles of association
      • Remuneration

Press releases

All press releases Regulatory

Press release 2022-12-13

Xspray presents novel scientific data for XS004 in the Chronic Myeloid Leukemia (CML) session at the 2022 Meeting of the American Society of Hematology

Press release 2022-11-30

Xspray Pharma’s drug candidate XS004 granted orphan drug designation in the US for the treatment of acute lymphoblastic leukemia

Regulatory press release 2022-11-09

Interim Report Third Quarter 2022

Press release 2022-11-03

Xspray Announces 2 Poster Presentations for XS004 in Chronic Myeloid Leukemia (CML) at the American Society of Hematology (ASH) 2022 Annual Meeting

Regulatory press release 2022-10-31

Number of shares and votes in Xspray Pharma

Regulatory press release 2022-10-25

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2023

Regulatory press release 2022-10-17

Xspray Pharma has carried out a directed share issue raising proceeds of MSEK 100

Regulatory press release 2022-08-05

Interim Report Second Quarter 2022

Regulatory press release 2022-06-17

Dasynoc granted Orphan Drug Designation in the US for the treatment of chronic myeloid leukemia

Regulatory press release 2022-06-15

Xspray Pharma appoints Thomas Walz as Chief Medical Officer

Show more

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe

  • This field is for validation purposes and should be left unchanged.
  • Submit to our press releases and get an email every time we publish a press release or report on our website.
  • When clicked on Send I agree that my personal information will be saved. Read more
Xspray-logo-white

Xspray Pharma AB Scheeles väg 2 171 65 Solna

+46 (0)8 730 37 00 info@xspraypharma.com